Haleon (LON:HLN), the pharmaceutical giant, has witnessed a major shift in its share dynamics recently. Institutions like
BlackRock,
Wellington Management Group and
Stifel Financial Corp have expanded their shareholding, while others, including
Fisher Asset Management, have downsized their stake. HighTower Advisors LLC, Fmr LLC, and Benjamin Edwards Inc. have further intensified their investments.
Pfizer, a major stakeholder, has decided to divest its shares, fetching approximately £2.4 billion in the process. Haleon is also actively involved in a
share buyback program to boost share value for investors. Despite its mixed financial performance, short sellers deem Haleon as a lucrative stock, supported by brokerages providing a consensus rating of 'Buy'. Drawing insight from leadership shifts, Haleon plc’s Director acquisition of shares signalizes confidence. However, there's an observed ambiguity over Haleon's future performance with tailwinds being mostly priced in.
Haleon Stocks News Analytics from Mon, 18 Mar 2024 07:00:00 GMT to Sat, 14 Dec 2024 08:35:32 GMT -
Rating 2
- Innovation 0
- Information 8
- Rumor -5
